<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Homoharringtonine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB04865</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Homoharringtonine, <span class="caps">AKA</span> <span class="caps">HHT</span> or omacetaxine mepesuccinate, is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Homoharringtonine  is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, homoharringtonine received Orphan Drug designation from the <span class="caps">EMEA</span> for the treatment of chronic myeloid leukemia (<span class="caps">CML</span>). Then in March 2006, homoharringtonine received Orphan Drug status from the <span class="caps">FDA</span> for the treatment of <span class="caps">CML</span>. In November 2006, homoharringtonine, for the treatment of <span class="caps">CML</span>, was granted Fast Track designation by the <span class="caps">FDA</span>. Most recently, in October 2012, homoharringtonine was marketed under the brand name Synribo&#8482; and <span class="caps">FDA</span> approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase <span class="caps">CML</span>.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB04865/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB04865/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04865.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04865.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04865.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04865.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04865.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB04865">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Cephalotaxus alkaloid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>CGX-635</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>HHT</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Myelostat</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>omacetaxine mepesuccinate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Ceflatonin</td><td>ChemGenex Therapeutics</td></tr><tr><td>SYNRIBO</td><td>IVAX INTL</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents">Antineoplastic Agents</a></li>
<li><a href="/mesh/angiogenesis-inhibitors">Angiogenesis Inhibitors</a></li>
<li><a href="/mesh/antineoplastic-agents-phytogenic">Antineoplastic Agents, Phytogenic</a></li></ul></td></tr><tr><th>CAS number</th><td>26833-87-4</td></tr><tr><th>Weight</th><td>Average: 545.6213<br>Monoisotopic: 545.262481851</td></tr><tr><th>Chemical Formula</th><td>C<sub>29</sub>H<sub>39</sub>NO<sub>9</sub></td></tr><tr><th>InChI Key</th><td>HYFHYPWGAURHIV-ZEDNPHJLSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25+,28-,29?/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2R,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0^{2,6}.0^{6,10}.0^{15,19}]icosa-1(13),4,14,19-tetraen-3-yl 1-methyl 3-hydroxy-3-(4-hydroxy-4-methylpentyl)butanedioate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12[C@H](OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCC1=CC3=C(OCO3)C=C21</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Erythrina Alkaloids</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Erythrina Alkaloids</td></tr><tr><th>Alternative parents</th><td>Benzazepines; Benzodioxoles; Beta Hydroxy Acids and Derivatives; Alkyl Aryl Ethers; Fatty Acid Esters; Azepines; Benzene and Substituted Derivatives; Dicarboxylic Acids and Derivatives; Pyrrolidines; Tertiary Alcohols; Tertiary Amines; Carboxylic Acid Esters; Enolates; Acetals; Polyamines; Aldehydes</td></tr><tr><th>Substituents</th><td>benzazepine; benzodioxole; succinic_acid; azepine; fatty acid ester; alkyl aryl ether; beta-hydroxy acid; benzene; hydroxy acid; dicarboxylic acid derivative; pyrrolidine; tertiary alcohol; carboxylic acid ester; tertiary amine; ether; carboxylic acid derivative; polyamine; acetal; enolate; alcohol; organonitrogen compound; amine; aldehyde</td></tr><tr><th>Classification description</th><td>This compound belongs to the erythrina alkaloids. These are organic compounds whose structure is based on a backbone contatining a indole-6-ol sharing its nitrogen atom with an isoquinoline ring system.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.  

</td></tr><tr><th>Pharmacodynamics</th><td>The pharmacodynamics of homoharringtonine is not fully understood. It is known that homoharringtonine is involved
with protein synthesis inhibition and this leads to its antineoplastic activity.
</td></tr><tr><th>Mechanism of action</th><td>Homoharringtonine inhibits protein synthesis by not directly binding to Bcr-Abl. It binds to the A-site cleft in the large ribosomal subunit, which affects chain elongation and prevents protein synthesis.

 </td></tr><tr><th>Absorption</th><td>Homoharringtonine absorption was not quantified, but maximum concentration is reached after about 30 mins. </td></tr><tr><th>Volume of distribution</th><td><p>Homoharringtonine has a steady state Vd of 141 &#177; 93.4 L.</p></td></tr><tr><th>Protein binding</th><td>Plasma protein binding is equal or less than 50%.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Homoharringtonine has undergoes little hepatic metabolism and is mostly metabolized to 4&#8217;-DMHHT by plasma esterase hydrolysis.

</p></td></tr><tr><th>Route of elimination</th><td>The main route of elimination for homoharringtonine is still unknown, but renal elimination is less than 15%.</td></tr><tr><th>Half life</th><td>Homoharringtonine has a half life of about 6 hours after subcutaneous administration.</td></tr><tr><th>Clearance</th><td><p>Clearance for homoharringtonine was not quantified.</p></td></tr><tr><th>Toxicity</th><td>The most severe adverse effects after homoharringtonine administration are myelosuppression, bleeding, hyperglycemia, and fetal harm.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8077</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.5157</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5102</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.9056</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5183</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8527</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7406</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8857</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7052</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7613</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9428</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5243
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.909
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.993
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1592 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9292
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8032
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder</td><td>Subcutaneous</td><td>3.5MG/VIAL </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Avoid combination with acetylsalicylic acid due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. </td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Avoid combination with ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. </td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Avoid combination due to the increased risk of infection.
</td></tr><tr><td><a href="/drugs/DB00337">Pimecrolimus</a></td><td>Avoid combination as there is potential to increase immunosuppressant adverse effects. 
</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Avoid combination as there is potential to increase immunosuppressant adverse effects. 
</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Avoid combination with tofacitinib and other potent immunosuppressants as there is potential to increase the immunosuppressant effects. Other less potent immunosuppressants such as methotrexate, at antirheumatic doses, and other non-disease modifying antirheumatic drugs (non-DMARDs) can be combined.  
</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Avoid combination with warfarin and other anticoagulants due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Homoharringtonine is administered subcutaneously, so food should have no effects. </li></ul></td></tr></tbody></table>